6月22日 - ** 药物研发公司Apogee Therapeutics（APGE.O）的股价在盘前交易中飙升54.4%，至139.5美元
** 《金融时报》周五报道称，艾伯维（Abbvie） ABBV.N 即将达成协议，以109亿美元现金收购APGE (link)
** 据报道，该交易对这家药物开发商的估值较周四收盘价溢价约60%
** 据伦敦证券交易所集团（LSEG）数据显示，截至上一交易日收盘，APGE的市值为68亿美元
** APGE已从黑石集团（Blackstone）获得13亿美元融资 (link)，用于开发实验性湿疹药物
** 截至上一交易日收盘，APGE股价年内累计上涨19.7%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.